Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-07-12 pm EDT			5-day change	1st Jan Change
224.2 ^USD	+2.16%		+7.72%	-3.12%

Jul. 10	Baird Adjusts Price Target on IQVIA to $235 From $241	MT
Jul. 09	Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating	MT

Biocomputing Platforms Ltd announced that it has received $15 million in funding from IQVIA Holdings Inc., Debiopharm Innovation Fund SA, Finnish Industry Investment Ltd

December 17, 2019

Biocomputing Platforms Ltd announced that it has received $15 million in a round of funding led by new investor IQVIA Holdings Inc. (NYSE:IQV) on December 18, 2019. The transaction included participation from new investor Debiopharm Innovation Fund SA and Finnish Industry Investment Ltd.

Latest news about Iqvia Holdings Inc.

Baird Adjusts Price Target on IQVIA to $235 From $241	Jul. 10	MT
Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating	Jul. 09	MT
Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07%	Jul. 09	CI
Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Bosutinib Tablets, 100 Mg and 500 Mg	Jul. 01	CI
Barclays Lowers Price Target on IQVIA Holdings to $255 From $275	Jun. 27	MT
Baird Adjusts Price Target on IQVIA Holdings to $241 From $245	Jun. 13	MT
IQVIA Launches ?One Home? Clinical Trial Technology Platform, Solves Challenges and Reduces Overload at Sitestes	Jun. 12	CI
Added health benefits of Wegovy, Zepbound could attract more men, doctors say	Jun. 10	RE
Goldman Sachs Initiates IQVIA With Buy Rating, $270 Price Target	Jun. 06	MT
Weight-loss drug forecasts jump to $150 billion as supply grows	May. 28	RE
Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM	May. 14
Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024	May. 10	CI
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294	May. 07	MT
UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating	May. 03	MT
Deutsche Bank Adjusts Price Target on IQVIA Holdings to $275 From $280	May. 03	MT
Jefferies Adjusts Price Target on IQVIA to $266 From $281	May. 03	MT
Morgan Stanley Adjusts Price Target on IQVIA to $270 From $275	May. 03	MT
Truist Adjusts IQVIA Holdings' Price Target to $292 From $297, Keeps Buy Rating	May. 03	MT
Baird Adjusts Price Target on IQVIA to $245 From $254	May. 03	MT
Leerink Partners Adjusts Price Target on IQVIA to $278 From $290	May. 03	MT
Evercore ISI Adjusts Price Target on IQVIA to $250 From $275	May. 03	MT
Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.	May. 02	CI
IQVIA trims full-year revenue forecast on stronger dollar	May. 02	RE
Transcript : IQVIA Holdings Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
IQVIA Holdings Inc. Reaffirms Guidance for the Full-Year of 2024	May. 02	CI

Chart Iqvia Holdings Inc.

Duration

Period

More charts

Company Profile

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Sector

Biotechnology & Medical Research

Calendar

2024-07-22 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Iqvia Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

224.2 USD

Average target price

269.2 USD

Spread / Average Target

+20.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-3.12%	40.84B
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-8.55%	11.14B

Other Biotechnology & Medical Research